HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System
HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.
Stocks · News reference
Dow Gains 100 Points; ISM Services PMI Falls In September
U.S. stocks rose Monday: Dow +0.2%, S&P 500 +0.62%, Nasdaq +0.84%. Materials led; ISM services PMI slipped to 54.9. Oil fell 1%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HeartBeam shares are trading higher after the company announced it received the FDA Breakthrough Device Designation for the HeartBeam System as a tool for assessing potential heart attacks at home.
US Stocks Mixed; Nasdaq Gains Over 50 Points
U.S. stocks mixed: Nasdaq and S&P 500 rose while Dow dipped. Weak jobs data pressured outlook; oil fell, while gold, silver and copper gained.
Why C.H Robinson Stock Was Tumbling Today
C.H. Robinson announced a $5.8 billion acquisition of RXO in a stock-and-cash deal, expecting $300 million in annual cost synergies. However, investors reacted negatively to the news, concerned about the company taking on approximately $3 billion in new debt and pausing share buybacks. C.H. Robinson stock fell 12.7% while RXO gained 21.9%.
Nasdaq 100 Hits Record, Brazil's EWZ Soars 13%: Stock Market Today
Nasdaq 100 hits a record as Brazil's EWZ jumps 13% on Bolsonaro's election upset; ISM services prices hit a four-year high and the 10-year yield tops 5.3%.
Why RXO Stock Soared Today
C.H. Robinson announced it will acquire RXO, the freight brokerage spun off from XPO in 2022, for $30.25 per share (a 29% premium). RXO shares surged 20.6%, while C.H. Robinson shares fell 14.6% as investors questioned the deal's value. The acquisition could face regulatory scrutiny due to C.H. Robinson's dominant market position, and the deal is expected to close in the first half of 2027.